Annexin Pharmaceuticals
0.469
SEK
-1.88 %
ANNX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
-1.88%
-4.48%
-6.2%
-33.94%
+71.79%
+91.68%
+16.84%
-35.13%
-41.81%
-85.68%
annexinpharma.com/investors
Annexin Pharmaceuticals is a biotechnology company with development in the Annexin A5 area. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for the treatment of patients with damage and inflammation in the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment and production of Annexin A5. The company was founded in 2014 and is based in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ANNX
Daily low / high price
0.456 / 0.47
SEK
Market cap
249.97M SEK
Turnover
16.94K SEK
Volume
37K
Financial calendar
Annual report
2025-02-06
Interim report
2025-04-16
General meeting
2025-05-15
Interim report
2025-07-17
Interim report
2025-10-23
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Mikael Lönn | 26.0 % | 26.0 % |
| Arne Andersson | 10.9 % | 10.9 % |
| Jahreskog, Sebastian | 9.3 % | 9.3 % |
| Avanza Pension | 9.2 % | 9.2 % |
| Claesson, Magnus | 8.2 % | 8.2 % |
| Lars Hallén | 3.8 % | 3.8 % |
| Nordnet Pensionsförsäkring AB | 3.0 % | 3.0 % |
| Willman, Mattias | 2.9 % | 2.9 % |
| Fridh, Thorbjörn | 2.4 % | 2.4 % |
| Medirista AB | 1.6 % | 1.6 % |
ShowingAll content types
Annexin Pharmaceuticals AB: Annexin Pharmaceuticals will present at the BioStock Life Science Summit, November 21
Annexin Pharmaceuticals AB: Annexin Pharmaceuticals presenterar på BioStock Life Science Summit 21 november
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools